Bill 119 HR 796, also known as the "Mifepristone Labeling Act," aims to amend the Federal Food, Drug, and Cosmetic Act to require a warning label on mifepristone, a medication used for medical abortions, advising that its effects can be counteracted. The bill also seeks to amend the Public Health Service Act to establish a hotline that provides information to women seeking to counteract the effects of mifepristone.
The purpose of this legislation is to ensure that women who have taken mifepristone are aware that there is a potential option to reverse its effects. By requiring a warning label on the medication packaging, women will be informed of the possibility of counteracting the medication if they change their minds after taking it.
Additionally, the establishment of a hotline will provide women with access to information and resources on how to reverse the effects of mifepristone. This hotline aims to support women who may be seeking to reverse the effects of the medication and make an informed decision about their reproductive health.
Overall, the Bill 119 HR 796 aims to provide women with more information and options regarding the effects of mifepristone, ultimately empowering them to make the best decision for their health and well-being.